Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1986; 79(Suppl 12): 13–18.
PMCID: PMC1290120

Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Vishwanath S, Ramphal R. Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun. 1984 Jul;45(1):197–202. [PMC free article] [PubMed]
  • Woods DE, Straus DC, Johanson WG, Jr, Berry VK, Bass JA. Role of pili in adherence of Pseudomonas aeruginosa to mammalian buccal epithelial cells. Infect Immun. 1980 Sep;29(3):1146–1151. [PMC free article] [PubMed]
  • Woods DE, Straus DC, Johanson WG, Jr, Bass JA. Role of salivary protease activity in adherence of gram-negative bacilli to mammalian buccal epithelial cells in vivo. J Clin Invest. 1981 Dec;68(6):1435–1440. [PMC free article] [PubMed]
  • Jagger KS, Bahner DR, Warren RL. Protease phenotypes of Pseudomonas aeruginosa isolated from patients with cystic fibrosis. J Clin Microbiol. 1983 Jan;17(1):55–59. [PMC free article] [PubMed]
  • Fick RB, Jr, Baltimore RS, Squier SU, Reynolds HY. IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis. 1985 Apr;151(4):589–598. [PubMed]
  • Klinger JD, Straus DC, Hilton CB, Bass JA. Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay. J Infect Dis. 1978 Jul;138(1):49–48. [PubMed]
  • Suter S, Schaad UB, Roux L, Nydegger UE, Waldvogel FA. Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J Infect Dis. 1984 Apr;149(4):523–531. [PubMed]
  • Berka RM, Gray GL, Vasil ML. Studies of phospholipase C (heat-labile hemolysin) in Pseudomonas aeruginosa. Infect Immun. 1981 Dec;34(3):1071–1074. [PMC free article] [PubMed]
  • Pollack M. The role of exotoxin A in pseudomonas disease and immunity. Rev Infect Dis. 1983 Nov-Dec;5 (Suppl 5):S979–S984. [PubMed]
  • Pollack M, Anderson SE., Jr Toxicity of Pseudomonas aeruginosa exotoxin A for human macrophages. Infect Immun. 1978 Mar;19(3):1092–1096. [PMC free article] [PubMed]
  • Martin DR. Mucoid variation in Pseudomonas aeruginosa induced by the action of phage. J Med Microbiol. 1973 Feb;6(1):111–118. [PubMed]
  • Govan JR, Fyfe JA. Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro. J Antimicrob Chemother. 1978 May;4(3):233–240. [PubMed]
  • Tejedor C, Foulds J, Zasloff M. Bacteriophages in sputum of patients with bronchopulmonary Pseudomonas infections. Infect Immun. 1982 Apr;36(1):440–441. [PMC free article] [PubMed]
  • Miller RV, Rubero VJ. Mucoid conversion by phages of Pseudomonas aeruginosa strains from patients with cystic fibrosis. J Clin Microbiol. 1984 May;19(5):717–719. [PMC free article] [PubMed]
  • Pier GB, Matthews WJ, Jr, Eardley DD. Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. J Infect Dis. 1983 Mar;147(3):494–503. [PubMed]
  • Irvin RT, Govan JW, Fyfe JA, Costerton JW. Heterogeneity of antibiotic resistance in mucoid isolates of Pseudomonas aeruginosa obtained from cystic fibrosis patients: role of outer membrane proteins. Antimicrob Agents Chemother. 1981 Jun;19(6):1056–1063. [PMC free article] [PubMed]
  • Thomassen MJ, Demko CA, Boxerbaum B, Stern RC, Kuchenbrod PJ. Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis. 1979 Dec;140(6):873–880. [PubMed]
  • Govan JR, Fyfe JA, Baker NR. Heterogeneity and reduction in pulmonary clearance of mucoid Pseudomonas aeruginosa. Rev Infect Dis. 1983 Nov-Dec;5 (Suppl 5):S874–S879. [PubMed]
  • Fonseca K, MacDougall J, Pitt TL. Inhibition of Pseudomonas aeruginosa from cystic fibrosis by selective media. J Clin Pathol. 1986 Feb;39(2):220–222. [PMC free article] [PubMed]
  • Slack MP, Nichols WW. The penetration of antibiotics through sodium alginate and through the exopolysaccharide of a mucoid strain of Pseudomonas aeruginosa. Lancet. 1981 Sep 5;2(8245):502–503. [PubMed]
  • Pitt TL. State of the art: typing Pseudomonas aeruginosa. J Hosp Infect. 1980 Sep;1(3):193–199. [PubMed]
  • Penketh A, Pitt T, Roberts D, Hodson ME, Batten JC. The relationship of phenotype changes in Pseudomonas aeruginosa to the clinical condition of patients with cystic fibrosis. Am Rev Respir Dis. 1983 May;127(5):605–608. [PubMed]
  • Hancock RE, Mutharia LM, Chan L, Darveau RP, Speert DP, Pier GB. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun. 1983 Oct;42(1):170–177. [PMC free article] [PubMed]
  • Pitt TL, Todd HC, Mackintosh CA, Im SW. Evaluation of three serological tests for detection of antibody to Pseudomonas aeruginosa in human sera. Eur J Clin Microbiol. 1985 Apr;4(2):190–196. [PubMed]
  • Lindberg U, Hanson LA, Jodal U, Lidin-Janson G, Lincoln K, Olling S. Asymptomatic bacteriuria in schoolgirls. II. Differences in escherichia coli causing asymptomatic bacteriuria. Acta Paediatr Scand. 1975 May;64(3):432–436. [PubMed]
  • Cryz SJ, Jr, Pitt TL, Fürer E, Germanier R. Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa. Infect Immun. 1984 May;44(2):508–513. [PMC free article] [PubMed]
  • Penketh AR, Pitt TL, Hodson ME, Batten JC. Bactericidal activity of serum from cystic fibrosis patients for Pseudomonas aeruginosa. J Med Microbiol. 1983 Nov;16(4):401–408. [PubMed]
  • Langford DT, Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results. Arch Dis Child. 1984 Dec;59(12):1131–1134. [PMC free article] [PubMed]
  • Sobel JD, Hashman N, Reinherz G, Merzbach D. Nosocomial Pseudomonas cepacia infection associated with chlorhexidine contamination. Am J Med. 1982 Aug;73(2):183–186. [PubMed]
  • Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, Levison H. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984 Feb;104(2):206–210. [PubMed]
  • Martin AJ, Smalley CA, George RH, Healing DE, Anderson CM. Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis. Arch Dis Child. 1980 Aug;55(8):604–607. [PMC free article] [PubMed]
  • McCrae WM, Raeburn JA, Hanson EJ. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum. J Infect Dis. 1976 Aug;134 (Suppl):S191–S193. [PubMed]
  • Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr. 1977 Jan;90(1):144–148. [PubMed]
  • Hoogkamp-Korstanje JA, van der Laag J. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis. J Antimicrob Chemother. 1983 Aug;12(2):175–183. [PubMed]
  • Møller NE, Koch C, Vesterhauge S, Jensen K. Treatment of pulmonary Pseudomonas aeruginosa infection in cystic fibrosis with cefsulodin. Scand J Infect Dis. 1982;14(3):207–211. [PubMed]
  • Scully BE, Neu HC. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria. Arch Intern Med. 1984 Jan;144(1):57–62. [PubMed]
  • Permin H, Koch C, Høiby N, Christensen HO, Møller AF, Møller S. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):313–323. [PubMed]
  • Lau WK, Young LS, Osher AB, Dooley RR. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Pediatrics. 1977 Sep;60(3):372–377. [PubMed]
  • Beaudry PH, Marks MI, McDougall D, Desmond K, Rangel R. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? J Pediatr. 1980 Jul;97(1):144–147. [PubMed]
  • Nolan G, Moivor P, Levison H, Fleming PC, Corey M, Gold R. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr. 1982 Oct;101(4):626–630. [PubMed]
  • Hodson ME, Penketh AR, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981 Nov 21;2(8256):1137–1139. [PubMed]
  • Wall MA, Terry AB, Eisenberg J, McNamara M, Cohen R. Inhaled antibiotics in cystic fibrosis. Lancet. 1983 Jun 11;1(8337):1325–1325. [PubMed]
  • Pier GB. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J Infect Dis. 1985 Apr;151(4):575–580. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press